• The FLOW trial showed that among patients with chronic kidney disease (CKD) and type 2 diabetes (T2D), once-weekly subcutaneous semaglutide was superior to placebo in improving renal and CV outcomes over a median follow-up of 3.4 years.
• In this analysis, the benefits of semaglutide in improving  renal outcomes were consistent in patients with/without baseline SGLT2i use

Continue reading →

• Obstructive sleep apnea is associated with cardiovascular complications and is seen more commonly in individuals with excess adiposity.
• The SURMOUNT OSA phase 3 trials evaluated the safety and efficacy of tirzepatide for the treatment of adults with obstructive sleep apnea and obesity.
• Tirzepatide reduced the AHI, body weight, hypoxic burden, hsCRP concentration, and systolic blood pressure and improved sleep-related patient-reported outcomes vs placebo in patients with moderate-to-severe obstructive sleep apnea and obesity.

Continue reading →

– Findings from cardiovascular trials suggested that fenofibrate therapy may reduce the progression of diabetic retinopathy.

– The LENS (Lowering Events in Non-proliferative retinopathy in Scotland) was a pragmatic trial to assess the effect of fenofibrate on the progression of retinopathy vs placebo conducted in Scotland.

-Fenofibrate was associated with a 27% reduction in the progression of diabetic retinopathy compared to placebo.

Continue reading →